Company Under Investigation:
NEXT Biometrics Group ASA
Documents used:
An analysis for the discerning investor, tracking the trail from the Q3 2025 restatements to the Q4 2025 strategic pivot.
NEXT Biometrics has spent the latter half of 2025 in a metaphorical "dust storm." The transition from Q3 to Q4 represents a company shifting from reactive damage control—stemming from a competitor's security failure in India and internal financial irregularities in China—to a more measured, if precarious, attempt at stability. The fundamental challenge remains: bridging the gap between high-tech promise and the cold reality of cash flow.
Despite the turbulent headlines, several pillars remain firmly in place:
While the strategy remains consistent, the operational environment has evolved significantly:
We must look at the narrative with a skeptical eye:
The Inventory Contradiction: Management consistently cites inventory as a path to future cash flow. However, as of Q4 2025, inventory write-downs are increasing (NOK 7.2 million). If the market is truly recovering as promised, why the necessity for significant write-downs? Investors should be wary of the assumption that all legacy inventory is "market-ready."
Revenue Recognition: The recurring theme of restatements and adjustments to revenue recognition reflects a struggle to align the operating business model with IFRS compliance. While the company claims these issues are "behind us," the continued reliance on distributor-side payment collection suggests that the company's "pull" on the market is still at the mercy of its distribution partners' health.
The outlook for 2026 rests on a specific inflection point: the normalization of the Indian market by Q3 2026. If the "Aadhaar certification backlog" truly clears, the company may see the revenue acceleration it forecasts (NOK 70 million target). However, the reliance on a rights issue to bridge the liquidity gap into 2027 implies that the market for biometric hardware remains cyclical and sensitive to government tender timelines—a risky "waiting game" for any private investor.
The Verdict: The company is attempting to pivot from a period of historical mismanagement and external market shocks toward a leaner, more R&D-heavy future. Success depends entirely on the conversion of current inventory to cash and the avoidance of further legal entanglements in the Chinese theater.